163 related articles for article (PubMed ID: 11812286)
1. Hexon gene switch strategy for the generation of chimeric recombinant adenovirus.
Youil R; Toner TJ; Su Q; Chen M; Tang A; Bett AJ; Casimiro D
Hum Gene Ther; 2002 Jan; 13(2):311-20. PubMed ID: 11812286
[TBL] [Abstract][Full Text] [Related]
2. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
Roberts DM; Nanda A; Havenga MJ; Abbink P; Lynch DM; Ewald BA; Liu J; Thorner AR; Swanson PE; Gorgone DA; Lifton MA; Lemckert AA; Holterman L; Chen B; Dilraj A; Carville A; Mansfield KG; Goudsmit J; Barouch DH
Nature; 2006 May; 441(7090):239-43. PubMed ID: 16625206
[TBL] [Abstract][Full Text] [Related]
3. Chimeric adenovirus 5/35 vector containing the clade C HIV gag gene induces a cross-reactive immune response against HIV.
Xin KQ; Sekimoto Y; Takahashi T; Mizuguchi H; Ichino M; Yoshida A; Okuda K
Vaccine; 2007 May; 25(19):3809-15. PubMed ID: 17386962
[TBL] [Abstract][Full Text] [Related]
4. Type-specific epitope locations revealed by X-ray crystallographic study of adenovirus type 5 hexon.
Rux JJ; Burnett RM
Mol Ther; 2000 Jan; 1(1):18-30. PubMed ID: 10933908
[TBL] [Abstract][Full Text] [Related]
5. Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses.
Bruder JT; Semenova E; Chen P; Limbach K; Patterson NB; Stefaniak ME; Konovalova S; Thomas C; Hamilton M; King CR; Richie TL; Doolan DL
PLoS One; 2012; 7(4):e33920. PubMed ID: 22496772
[TBL] [Abstract][Full Text] [Related]
6. Construction and characterization of a recombinant human adenovirus type 3 vector containing two foreign neutralizing epitopes in hexon.
Xue C; Tian X; Li X; Zhou Z; Su X; Zhou R
Virus Res; 2014 Apr; 183():67-74. PubMed ID: 24518297
[TBL] [Abstract][Full Text] [Related]
7. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein.
Sumida SM; Truitt DM; Lemckert AA; Vogels R; Custers JH; Addo MM; Lockman S; Peter T; Peyerl FW; Kishko MG; Jackson SS; Gorgone DA; Lifton MA; Essex M; Walker BD; Goudsmit J; Havenga MJ; Barouch DH
J Immunol; 2005 Jun; 174(11):7179-85. PubMed ID: 15905562
[TBL] [Abstract][Full Text] [Related]
8. Construction and characterization of human adenovirus serotype 3 packaged by serotype 7 hexon.
Tian X; Su X; Li H; Li X; Zhou Z; Liu W; Zhou R
Virus Res; 2011 Sep; 160(1-2):214-20. PubMed ID: 21740937
[TBL] [Abstract][Full Text] [Related]
9. Circumvention of immunity to the adenovirus major coat protein hexon.
Roy S; Shirley PS; McClelland A; Kaleko M
J Virol; 1998 Aug; 72(8):6875-9. PubMed ID: 9658137
[TBL] [Abstract][Full Text] [Related]
10. Binding of adenovirus species C hexon to prothrombin and the influence of hexon on vector properties in vitro and in vivo.
Tian J; Xu Z; Moitra R; Palmer DJ; Ng P; Byrnes AP
PLoS Pathog; 2022 Sep; 18(9):e1010859. PubMed ID: 36156097
[TBL] [Abstract][Full Text] [Related]
11. [Immunogenicity of a chimeric adenovirus type 5 vector with type 35 fiber containing HIV-1 gag in mice].
Liu XL; Yu SQ; Feng X; Wang XL; Liu HM; Zhang XM; Li HX; Zhou L; Li ZL; Zheng Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Mar; 21(1):5-7. PubMed ID: 17429520
[TBL] [Abstract][Full Text] [Related]
12. Decreased immune reactivity towards a knobless, affibody-targeted adenovirus type 5 vector.
Myhre S; Henning P; Granio O; Tylö AS; Nygren PA; Olofsson S; Boulanger P; Lindholm L; Hong SS
Gene Ther; 2007 Feb; 14(4):376-81. PubMed ID: 17036056
[TBL] [Abstract][Full Text] [Related]
13. Designed recombinant adenovirus type 5 vector induced envelope-specific CD8(+) cytotoxic T lymphocytes and cross-reactive neutralizing antibodies against human immunodeficiency virus type 1.
Ura T; Yoshida A; Xin KQ; Yoshizaki S; Yashima S; Abe S; Mizuguchi H; Okuda K
J Gene Med; 2009 Feb; 11(2):139-49. PubMed ID: 19065543
[TBL] [Abstract][Full Text] [Related]
14. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype.
Mack CA; Song WR; Carpenter H; Wickham TJ; Kovesdi I; Harvey BG; Magovern CJ; Isom OW; Rosengart T; Falck-Pedersen E; Hackett NR; Crystal RG; Mastrangeli A
Hum Gene Ther; 1997 Jan; 8(1):99-109. PubMed ID: 8989999
[TBL] [Abstract][Full Text] [Related]
15. Expression of an antigenic adenovirus epitope in a group B coxsackievirus.
Höfling K; Tracy S; Chapman N; Kim KS; Smith Leser J
J Virol; 2000 May; 74(10):4570-8. PubMed ID: 10775593
[TBL] [Abstract][Full Text] [Related]
16. Identification of a suppressor mutation that improves the yields of hexon-modified adenovirus vectors.
Bruder JT; Chen P; Semenova E; Thomas CA; Konovalova S; Ekberg G; Ettyreddy D; McVey D; Gall JG; King CR; Brough DE
J Virol; 2013 Sep; 87(17):9661-71. PubMed ID: 23824800
[TBL] [Abstract][Full Text] [Related]
17. Pseudopackaging of adenovirus type 5 genomes into capsids containing the hexon proteins of adenovirus serotypes B, D, or E.
Ostapchuk P; Hearing P
J Virol; 2001 Jan; 75(1):45-51. PubMed ID: 11119572
[TBL] [Abstract][Full Text] [Related]
18. [Structural and immunochemical analysis of the products of proteolysis of simian adenovirus hexons].
Grigor'ev VG; Khil'ko SN; Tikhonenko TI
Mol Biol (Mosk); 1985; 19(6):1525-36. PubMed ID: 2417106
[TBL] [Abstract][Full Text] [Related]
19. Interaction between hexon and L4-100K determines virus rescue and growth of hexon-chimeric recombinant Ad5 vectors.
Yan J; Dong J; Wu J; Zhu R; Wang Z; Wang B; Wang L; Wang Z; Zhang H; Wu H; Yu B; Kong W; Yu X
Sci Rep; 2016 Mar; 6():22464. PubMed ID: 26934960
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection.
Bradley RR; Lynch DM; Iampietro MJ; Borducchi EN; Barouch DH
J Virol; 2012 Jan; 86(1):625-9. PubMed ID: 22072776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
